Notícias Immuneering Corporation - IMRX | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Immuneering Corporation (IMRX)
Immuneering Corporation (IMRX) Notícias

Immuneering Corporation (IMRX)

1,90

-0,09

(-4,52%)

Fechado 09 Fevereiro 6:00PM

Atrasado por 15 minutos

1,90

0,00

(0,00%)

Após o horário de negociação: 9:58PM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições